ApoE4 and Mitochondrial Function in Alzheimer’s Disease

Chaeyoung Kim, PhD
Gladstone Institutes (San Francisco, CA)


Robert W. Mahley, MD, PhD
The J. David Gladstone Institutes
Year Awarded:
Grant Duration:
July 1, 2017 to June 30, 2019
Alzheimer's Disease
Award Amount:
Grant Reference ID:
Award Type:
Postdoctoral Fellowship
Award Region:
US Northwestern
Chaeyoung Kim, PhD

As a young adult, I witnessed the tragedy of dementia firsthand.

Read More

Apolipoprotein E4, Mitochondrial Function and Alzheimer's Disease


Apolipoprotein E (apoE) has important roles in both normal central nervous system physiology and neuropathology, such as Alzheimer’s disease (AD). Importantly, the apoE4, one of apoE isoforms, is the major genetic risk factor for AD, and generates toxic fragments that cause mitochondrial dysfunction and drive neurodegeneration. Because mitochondrial dysfunction and metabolic impairment are critical elements of AD pathology, I will study how apoE4 and its neurotoxic fragments interact with mitochondria and alter mitochondrial activity. This largely unexplored approach will provide insight into the mechanisms underlying the role of apoE4 in AD and may identify new therapeutic targets to treat apoE4-associated AD.


We aim to determine how apoE4, the major genetic risk factor for AD, and its neurotoxic fragments disrupt mitochondrial activity to drive neurodegeneration.

Approximately 65–70 percent of patients with AD carry the apoE4 gene, and about 25 percent of Americans have at least one copy of the apoE4 allele. Yet, we do not fully understand how apoE4 causes neurodegeneration.  

In neurons, apoE4 is cleaved into fragments that affect the function of mitochondria, the energy powerhouses of cells. This effect is an early pathological event in AD. We linked apoE4 fragments and mitochondrial dysfunction to neurodegeneration, and we are working to understand the mechanism underlying this relationship. Specifically, we are studying whether apoE4 causes neurodegeneration by altering energy (ATP) production and calcium buffering, two important functions of mitochondria. We are also identifying which metabolic pathways in mitochondria are altered by apoE4. To do this, we are expressing apoE4 and apoE3 (a neutral form of apoE) in cultured neurons and using functional assays to analyze how they affect metabolic activity. We are also expressing these forms in a transgenic mouse to analyze metabolic activity in primary neurons and synaptosomes. 

 We identified a protein that directly binds to apoE4 and its fragments. This protein is the main channel in the outer membrane of mitochondria that regulates mitochondrial function, including the flux of mitochondrial metabolites, ATP/ADP, and calcium. We are now evaluating how apoE4 fragments interact with this protein to cause mitochondrial dysfunction and neurodegeneration. Specifically, we aim to identify the structural domains of apoE4 that interact with the protein and whether apoE4 fragments bind to and inhibit its function. In addition, we want to determine if and how apoE4 fragments enter mitochondria. To do this, we will locate the apoE4 fragments in cultured neurons and determine how they affect the cells. Also, with site-direct mutagenesis, we will identify which domains in apoE4 bind to the protein we discovered and how apoE4 fragments alter its function.

Most studies compared the effects of apoE3 and apoE4 on beta-amyloid deposition or clearance. However, apoE4 also appears to directly and independently affect neuropathology. We are investigating how apoE4 causes mitochondrial dysfunction, a key component or even a primary driver of pathology in AD. We are also determining how apoE4 disrupts mitochondrial function to cause neurodegeneration. Our innovative approach arises from our many years of studying the structure and function of apoE and how apoE4 influences mitochondrial function and neurodegeneration.

ApoE4 is the greatest known genetic risk factor for AD, but how apoE4 affects the pathogenesis of the disease is unclear. We are working to link apoE4-induced mitochondrial dysfunction with decreased survival of neurons in AD. We believe that our work will advance our understanding of exactly how apoE4 influences AD pathogenesis and will reveal new therapeutic targets to treat the disease.

About the Researcher

Dr. Chaeyoung Kim is a postdoctoral scholar with Dr. Robert Mahley at the Gladstone Institutes and the University of California, San Francisco. She studies the mechanisms underlying the pathology of Alzheimer’s disease related to apolipoprotein E and mitochondria. Before joining Gladstone, Dr. Kim was a postdoctoral fellow at the Mayo Clinic, where she studied the effects of post-translational modifications on Alzheimer’s pathology. Dr. Kim earned her PhD in neuroscience from Seoul National University, her MS in biology from Yonsei University, and her BS in life science from The University of Seoul. Dr. Kim received The Honorable Mention Award for Excellence in Research on Alzheimer’s and Related Disorders from the Alzheimer’s Association.

Personal Story

As a young adult, I witnessed the tragedy of dementia firsthand. My grandmother essentially raised me, but by the time she died, she could not recognize me or remember times we had together. Since then, I have dedicated my life to finding a cure for this devastating disease. Also, as people are living longer, the incidence of Alzheimer’s disease is increasing. Many more patients will drift away from their families, and healthcare costs will rise. We urgently need to better understand the pathology underlying the disease so we can develop effective therapies. With support from the BrightFocus Foundation, we are that much closer to developing revolutionary treatments, preventions, and cures for this tragic condition. 

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.